Jiebin Dong

Title: Jiebin Dong: Innovator in Senolytic and Anti-inflammatory Prodrugs

Introduction

Jiebin Dong is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of senolytic and anti-inflammatory prodrugs. His innovative work aims to address age-related diseases and inflammatory disorders.

Latest Patents

Jiebin Dong holds a patent for "Senolytic and anti-inflammatory prodrugs and methods of use thereof." This patent describes prodrugs designed from a cytotoxic agent, which are chemically modified to incorporate a site cleavable by SA-β-gal. This modification allows for the release of the active parent drug following in vivo delivery. The prodrug includes a galactose-based moiety, preferably acetylated, along with a benzyl oxy carboxy group and a cytotoxic agent moiety. The selenolytic prodrug is intended to selectively kill senescent cells and reduce acute or chronic inflammatory responses in subjects in need. The disclosed compositions can alleviate symptoms associated with senescence-associated diseases or inflammatory disorders, such as virus-mediated inflammation.

Career Highlights

Jiebin Dong is affiliated with Peking University, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on treating age-related conditions and inflammatory diseases.

Collaborations

Jiebin Dong collaborates with notable colleagues, including Hongkui Deng and Tuoping Luo. Their combined expertise contributes to the innovative research being conducted at Peking University.

Conclusion

Jiebin Dong's contributions to the field of pharmaceuticals, particularly through his patent on senolytic and anti-inflammatory prodrugs, highlight his role as an influential inventor. His work has the potential to significantly improve the treatment of age-related and inflammatory disorders.